Goldman Sachs’s PTC Therapeutics PTCT Stock Holding History

Goldman Sachs’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-27,500	Closed	-$1.4M	–	5503
2020 Q2	$1.4M	Buy	+27,500	New	+$1.35M	﹤0.01%	3727
2018 Q2	–	Sell	-96,000	Closed	-$2.6M	–	5933
2018 Q1	$2.6M	Buy	+96,000	New	+$2.43M	﹤0.01%	3403
2017 Q1	–	Sell	-59,000	Closed	-$644K	–	6955
2016 Q4	$644K	Buy	+59,000	New	+$619K	﹤0.01%	4831
2016 Q1	–	Sell	-16,200	Closed	-$525K	–	7267
2015 Q4	$525K	Sell	16,200 -88,900	-85%	-$2.62M	﹤0.01%	4881
2015 Q3	$2.81M	Buy	105,100 +88,400	+529%	+$3.78M	﹤0.01%	3438
2015 Q2	$804K	Sell	16,700 -47,500	-74%	-$2.77M	﹤0.01%	4729
2015 Q1	$3.91M	Buy	+64,200	New	+$3.92M	﹤0.01%	3130

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Goldman Sachs's PTCT Position: Q2 2026 in Review

Goldman Sachs reduced its PTC Therapeutics (PTCT) stake by 25% in Q2 2026, selling an estimated $15.1M and leaving 618,247 shares worth $50.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1795.

Goldman Sachs first reported a position in PTCT in Q3 2013 and has held it in 50 quarters since. The position peaked at $77.7M in Q4 2025. 383 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Goldman Sachs held 618,247 shares of PTC Therapeutics worth $50.4M as of Q2 2026.
Goldman Sachs sold 209,384 PTC Therapeutics shares in Q2 2026, an estimated $15.1M.
PTC Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #1795 holding.
Goldman Sachs first reported a position in PTC Therapeutics in Q3 2013 and has held it in 50 quarters since.
Goldman Sachs's PTC Therapeutics position peaked at $77.7M in Q4 2025.
383 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.